Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of Novartis
arcticnovartis
Mon, 03/31/2025 – 07:04
Read more about Novartis …
Entries by arcticnovartis
FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer
arcticnovartis
Fri, 03/28/2025 – 17:58
Read more about FDA approves Novartis radioligand thera…
Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis
arcticnovartis
Tue, 03/25/2025 – 07:18
Read more about Novartis to present new data at AAN, …
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
arcticnovartis
Fri, 03/21/2025 – 00:19
Read more about Novartis receives third FDA approval for oral Fabhalta® (…
New Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA
arcticnovartis
Wed, 03/19/2025 – 14:04
Read more about New Novartis Phase III data demonstr…
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2025 Annual General Meeting
arcticnovartis
Fri, 03/07/2025 – 15:19
Read more about Novartis shareholders approve all resolutions proposed by the Board of Direc…
Aktionäre von Novartis heissen an der Generalversammlung 2025 alle Anträge des Verwaltungsrats gut
arcticnovartis
Fri, 03/07/2025 – 15:19
Read more about Aktionäre von Novartis heissen an der Generalversammlung 2025 alle Anträge des Verwaltungsrat…
Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)
arcticnovartis
Fri, 02/28/2025 – 15:04
Read more about Novartis data presentations a…
Novartis oral Fabhalta® (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G)
arcticnovartis
Fri, 02/28/2025 – 13:49
Read more about Novartis oral Fabhalta® (iptacopan) receives positive CHMP op…
Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront
arcticnovartis
Tue, 02/11/2025 – 07:19
Read more about Novartis bolsters late-stage cardiovascular pipeline with agreeme…